2018年美国心脏协会血脂管理指南解读
吴娜琼,李建军
摘要(Abstract)：
<正>2018年美国心脏协会(AHA)年会在芝加哥召开,公布2018版AHA血脂管理指南(简称2018版指南)[1],迅速引起业内的广泛关注和众多专家的解读,充分说明血脂领域进展迅速,心血管医师急需一份指南汇总近些年来血脂领域大量新的循证证据,以便在临床实践中及时更新和应用。2018版指南共120页,从撰写形式上与2013版AHA血脂管理指南(简称2013版指南)有所不同[2],以方便使用者快速提取核心内容。2018
关键词(KeyWords)： 血脂管理;指南;解读
基金项目(Foundation):
作者(Author): 吴娜琼,李建军
参考文献(References)：
- [1]Grundy SM,Stone NJ,Bailey AL,et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.J Am coll Cardiol,2018.[Epub ahead of print].
- [2]Stone NJ,Robinson JG,Lichtenstein AH,et al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association task force on practice guidelines.Circulation,2014,129(25 Suppl2):S1-S45.
- [3]Ray KK,Kastelein JJ,Boekholdt SM,et al.The ACC/AHA2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults:the good the bad and the uncertain:a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.Eur Heart J,2014,35(15):960-968.
- [4]Lloyd-Jones DM,Morris PB,Ballantyne CM,et al.2016ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk:a report of the American College of Cardiology task force on clinical expert consensus documents.J Am Coll Cardiol,2016,68(1):92-125.
- [5]Bohula EA,Giugliano RP,Cannon CP,et al.Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.Circulation,2015,132(13):1224-1233.
- [6]Bonaca MP,Nault P,Giugliano RP,et al.Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease:insights from the FOURIER trial(further cardiovascular outcomes research With PCSK9 inhibition in subjects with elevated risk).Circulation,2018,137(4):338-350.
- [7]Pencina MJ,D'Agostino RB Sr,Larson MG,et al.Predicting the 30-year risk of cardiovascular disease:the framingham heart study.Circulation,2009,119(24):3078-3084.
- [8]Yusuf S,Bosch J,Dagenais G,et al.Cholesterol lowering in intermediate-risk persons without cardiovascular disease.N Engl JMed,2016,374(21):2021-2031.